Skip to main content
Let's spread the word about Immunotherapy! Click to share this page with your community.

Immunotherapy Fact of the Day: Some immune cells attack cancer directly, while others help coordinate the response.

Some immune cells attack cancer directly, while others help coordinate the response.

Just like any well-trained force, our immune cells divide the labor, too.

Some, like T cells, attack tumors directly. Others, such as dendritic cells (DCs), orchestrate attacks from behind the scenes. By gathering intelligence about a tumor’s markers (antigens), DCs can then educate other immune what the tumor “looks like.”

This “education,” which often takes place in the lymph nodes, occurs through a system of surface receptors called MHC (major histocompatibility complex) that present tumor antigens. The MHC/antigen system is what gives the adaptive immune system the ability to recognize and respond to threats, including cancer and infection. (The MHC2 molecule was discovered by Peter Cresswell, Ph.D. , while Emil R. Unanue, M.D., and Rolf M. Zinkernagel, M.D., Ph.D., also made major contributions to our understanding of MHC activity.)

Because of this ability to coordinate anti-tumor responses, DCs—which were discovered by Ralph Steinmann, M.D.—have been incorporated into several immunotherapy approaches including Sipuleucel-T, an FDA-approved prostate cancer vaccine that uses a patient’s own DCs.

The following CRI-funded scientists are investigating the factors that influence the MHC/antigen system and adaptive immune responses, as well as evaluating novel DC-based immunotherapy approaches for patients:

Image credit: Creative Commons via U.S. Air Force Live (The Official Blog of the U.S. Air Force)

*Immunotherapy results may vary from patient to patient.